N-[2-[5-[2,4-bis(trifluoromethyl)phenyl]-3-(2,2-dimethylpropyl)indol-1-yl]ethyl]cyclopentanesulfonamide
C28H32F6N2O2S — CID 166911114
Data last refreshed: (MolForge compound catalog, from PubChem)
About N-[2-[5-[2,4-bis(trifluoromethyl)phenyl]-3-(2,2-dimethylpropyl)indol-1-yl]ethyl]cyclopentanesulfonamide
N-[2-[5-[2,4-bis(trifluoromethyl)phenyl]-3-(2,2-dimethylpropyl)indol-1-yl]ethyl]cyclopentanesulfonamide (PubChem CID 166911114) has the molecular formula C28H32F6N2O2S and a molecular weight of 574.63 g/mol. Its IUPAC name is N-[2-[5-[2,4-bis(trifluoromethyl)phenyl]-3-(2,2-dimethylpropyl)indol-1-yl]ethyl]cyclopentanesulfonamide.
Molecular Properties
| Compound Name | N-[2-[5-[2,4-bis(trifluoromethyl)phenyl]-3-(2,2-dimethylpropyl)indol-1-yl]ethyl]cyclopentanesulfonamide |
|---|---|
| PubChem CID | 166911114 |
| Molecular Formula | C28H32F6N2O2S |
| Molecular Weight | 574.63 g/mol |
| Exact Mass | 574.21 |
| IUPAC Name | N-[2-[5-[2,4-bis(trifluoromethyl)phenyl]-3-(2,2-dimethylpropyl)indol-1-yl]ethyl]cyclopentanesulfonamide |
| SMILES | CC(C)(C)Cc1cn(CCNS(=O)(=O)C2CCCC2)c2ccc(-c3ccc(C(F)(F)F)cc3C(F)(F)F)cc12 |
| InChI | InChI=1S/C28H32F6N2O2S/c1-26(2,3)16-19-17-36(13-12-35-39(37,38)21-6-4-5-7-21)25-11-8-18(14-23(19)25)22-10-9-20(27(29,30)31)15-24(22)28(32,33)34/h8-11,14-15,17,21,35H,4-7,12-13,16H2,1-3H3 |
| InChIKey | ITCQJZSKPUOFMS-UHFFFAOYSA-N |
| XLogP | 7.80 |
| TPSA | 51.10 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 3 |
| Rotatable Bonds | 7 |
| Heavy Atoms | 39 |
| Complexity | — |
Lipinski Rule of Five
2 violations
| Rule | Value |
|---|---|
| MW ≤ 500 | 574.63 |
| LogP ≤ 5 | 7.80 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 3 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 166911114 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.